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Solubility and dissolution rate of drugs are of major importance in pre-formulation studies of pharmaceutical 
dosage forms. The solubility improvement allows the drugs to be potential biowaiver candidates and may 
be a good way to develop more dose-efficient formulations. Solubility behaviour of lamivudine, stavudine 
and zidovudine in individual solvents (under pH range of 1.2 to 7.5) was studied by equilibrium solubility 
and intrinsic dissolution methods. In solubility study by equilibrium method (shake-flask technique), 
known amounts of drug were added in each media until to reach saturation and the mixture was subjected 
to agitation of 150 rpm for 72 hours at 37 °C. In intrinsic dissolution test, known amount of each drug was 
compressed in the matrix of Wood’s apparatus and subjected to dissolution in each media with agitation 
of 50 rpm at 37 °C. In solubility by equilibrium method, lamivudine and zidovudine can be considered as 
highly soluble drugs. Although stavudine present high solubility in pH 4.5, 6.8, 7.5 and water, the solubility 
determination in pH 1.2 was not possible due stability problems. Regarding to intrinsic dissolution, 
lamivudine and stavudine present high speed of dissolution. Considering a boundary value presented by 
Yu and colleagues (2004), all drugs studied present high solubility characteristics in intrinsic dissolution 
method. Based on the obtained results, intrinsic dissolution seems to be superior for solubility studies as 
an alternative method for biopharmaceutical classification purposes.
Uniterms: Drugs/solubility. Drugs/dissolution rate. Intrinsic dissolution/method/biopharmaceutical 
classification. Biopharmaceutical Classification System.
A solubilidade e a taxa de dissolução de fármacos são de grande importância em estudos de pré-
formulação de formas farmacêuticas. A melhora na solubilidade permite que os fármacos sejam candidatos 
potenciais à bioisenção, podendo ser uma boa maneira para desenvolver formulações dose-eficientes. O 
comportamento de solubilidade da lamivudina, estavudina e zidovudina em solventes individuais (sob 
faixa de pH 1,2 a 7,5) foi estudado pelos métodos de solubilidade em equilíbrio e dissolução intrínseca. 
No estudo de solubilidade pelo método do equilíbrio (método de agitação de frascos), conhecidas 
quantidades do fármaco foram adicionadas em cada meio até atingirem a saturação e a mistura foi 
submetida à agitação de 150 rpm por 72 horas a 37 °C. No ensaio de dissolução intrínseca, conhecida 
quantidade de cada fármaco foi comprimida na matriz do aparato de Wood e submetida à dissolução em 
cada meio com agitação de 50 rpm a 37 °C. No método de solubilidade em equilíbrio, a lamivudina e a 
zidovudina podem ser consideradas como fármacos altamente solúveis. Embora a estavudina apresente 
alta solubilidade nos meios pH 4,5, 6,8, 7,5 e água, a determinação da solubilidade em pH 1,2 não foi 
possível devido a problemas de estabilidade. Com relação à dissolução intrínseca, a lamivudina e a 
estavudina apresentaram alta velocidade de dissolução. Considerando o valor limite apresentado por Yu e 
colaboradores (2004), todos os fármacos apresentaram características de alta solubilidade no método de 
dissolução intrínseca. Com base nos resultados obtidos, a dissolução intrínseca parece ser superior para os 
estudos de solubilidade como um método alternativo para o propósito de classificação biofarmacêutica.
Unitermos: Fármacos/solubilidade. Fármacos/taxa de dissolução. Dissolução intrínseca/método/
classificação biofarmacêutica. Sistema de Classificação Biofarmacêutica.
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INTRODUCTION
Biopharmaceutical Classification System (BCS) 
is a scientific tool proposed by Amidon and colleagues 
(1995) and it is based on aqueous solubility and intestinal 
permeability characteristics of drug substances. Thereby, 
the drugs can be classified into four classes: class I (high 
solubility and high permeability), class II (low solubility 
and high permeability), class III (high solubility and 
low permeability), and class IV (low solubility and 
low permeability) (Amidon et al., 1995; Lennernäs, 
Abrahamsson, 2005; Löbenberg, Amidon, 2000; United 
States, 2000).
The BCS is used to develop new pharmaceutical 
formulations, it assists in biowaiver processes for class 
I drugs as a regulatory tool and it predicts the in vivo 
behavior of a compound (Amidon et al., 1995; EMA, 
2001; United States, 2000).
In 2000, a guide published by FDA (Food and 
Drug Administration), based on BCS, provides waiver 
for bioavailability and bioequivalence studies in vivo for 
immediate release dosage forms (class I drugs) (United 
States, 2000). Thus, it is possible to reduce time, costs 
and exposure of healthy volunteers to develop new 
medicinal products (Chen, Yu, 2009; Cook, Addicks, Wu, 
2008; Lennernäs, 2007; Lennernäs, Abrahamsson, 2005; 
Lindenberg, Kopp, Dressman, 2004; Lobenberg, Amidon, 
2000; United States, 2000).
For a biowaiver process, FDA guidance (2000) 
recommends solubility and permeability tests in order to 
classify drugs according to BCS (United States, 2000).
For permeability studies, several methods can be 
used to determine intestinal permeability of drugs such 
as: in situ intestinal perfusion in animals or humans (in 
vivo perfusion), in vitro permeation studies using artificial 
membranes or cell culture monolayers and ex vivo method 
using isolated intestinal segment (Dezani et al., 2013; Reis 
et al., 2013 United States, 2000).
The methods most recommended for solubility 
studies are: equilibrium method (shake-flask technique) 
and acid or base titration methods (employment must 
be justified). In the equilibrium solubility method, the 
evaluation of drug is achieved with the addition of an 
amount of substance in an aqueous solvent until it reaches 
the saturation of the media, followed by stirring for a 
prolonged period until the attainment of equilibrium 
(Avdeef, 2003; EMA, 2008; United States, 2000).
Solubility studies must be conducted under 
physiological pH 1.0 – 7.5 according to FDA guidance, 
while for EMA (European Medicines Agency) the pH 
range should be between 1.2 and 6.8, with test temperature 
of 37.0 ± 1 °C (EMA, 2008; United States, 2000).
The solubility test allows to obtain the dose:solubility 
ratio, which corresponds to the ratio between the highest 
dose available in a pharmaceutical product and the 
solubility of the drug. Thus, according to FDA guidance, 
highly soluble drugs exhibit dose:solubility ratio less than 
250 mL in a pH range of 1.0 to 7.5 at 37 °C (Lindenberg, 
Kopp, Dressman, 2004; United States, 2000).
Other method for solubility studies, the intrinsic 
dissolution, has been used to characterize solid drugs 
(Amidon, Higuchi, Ho, 1982; Yu, Amidon, 1999; Yu et 
al., 2004; Zakeri-Milani et al., 2009). This property has 
been studied in order to elucidate the relationship between 
the dissolution rate and the crystalline form. In addition, 
it is possible to determinate a dissolution profile of a 
drug and also study the surfactants and pH effects on the 
dissolution of poorly soluble drugs (Chan, Grant, 1989; 
Dahlan, McDonald, Sunderland, 1987; Jinno et al., 2000; 
Wadke, Reier, 1972; Yu et al., 2004).
The intrinsic dissolution rate (IDR) is generally 
defined as the dissolution rate of a drug under constant 
surface area, stirring speed, pH and ionic strength of the 
dissolution media. The effective IDR is described as the 
rate of mass transferred from the solid surface to the liquid 
phase (Yu et al., 2004; Zakeri-Milani et al., 2009).
For the application of IDR and equilibrium methods for 
solubility studies, antiretroviral drugs were used in this study.
Lamivudine (3TC), stavudine (d4T) and zidovudine 
(AZT) are some examples of nucleoside reverse 
transcriptase inhibitors for HIV (Human Immunodeficiency 
Virus) treatment (Aymard et al., 2000; Balint, 2001; Checa 
et al., 2005). Solubility data related to these antiretroviral 
drugs are scarce in the literature.
Based on these conditions, the present study aims 
to evaluate the solubility behavior of 3TC, d4T and AZT 
using equilibrium solubility and intrinsic dissolution, 
and compare the results between these methods for 
BCS application, since steps such as disintegration and 
dissolution of a solid dosage form are crucial for drug 
release and subsequent absorption and bioavailability.
MATERIAL AND METHODS
Buffers
Four buffer solutions were prepared from different 
proportions of hydrochloric acid, monobasic potassium 
phosphate (0.2 M) and sodium hydroxide (solution 
0.2 M), as follows: pH 1.2 (HCl), pH 4.5 (KH2PO4), pH 
6.8 (KH2PO4 and NaOH), pH 7.5 (KH2PO4 and NaOH).
High purity deionised water was obtained from 
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Milli-Q purification system (Millipore, MA, USA) and 
used for components dissolution. The pH values were 
adjusted using HCl 0.1 M and NaOH 0.2 M solutions.
All dissolution media were prepared according to 
USP XXXIII, British Pharmacopoeia and Portuguese 
Pharmacopeia IX (British Pharmacopoeia, 2009; 
Farmacopéia Portuguesa IX, 2008; United States 
Pharmacopeia, 2010).
Equilibrium solubility method (shake-flask)
Solubility studies of antiretroviral drugs were 
determined by equilibrating excess amount of each drug in 
buffer solutions of pH 1.2, 4.5, 6.8, 7.5 and purified water.
Assays were performed in plastic flasks with a 
capacity of 50 mL. In each flask were added 10 mL of 
media and the amount of drug separately. The amount was 
sufficient to saturate each media, which was characterized 
by depositing of substance not solubilized.
Incubator shaker was used to keep samples at 37 °C 
during the test with agitation of 150 rpm for 72 hours 
(until achieve the equilibrium condition) (Marín, Margarit, 
Salcedo, 2002; Okumu, Dimaso, Löbenberg, 2009; United 
States, 2000; Won et al., 2005). After this period, samples 
were immediately filtered (0.45 µm) and diluted in a 
volumetric flask with the corresponding media.
For quantification processes of antiretroviral drugs, a 
UV-Vis spectrophotometer (Varian) was used at maximum 
absorbance wavelength for each media and the solubility 
values were calculated using calibration curves determined 
for each substance.
With solubility results, the dose:solubility ratio 
was calculated, which is obtained by dividing the highest 
commercially available dose of the drug (in milligrams) 
by the solubility (in milligrams per milliliter) obtained 
in the study. The values of the dose:solubility ratio are 
then compared with the criteria established by the FDA 
guidance to verify if the drug is highly soluble or not 
(Lindenberg, Kopp, Dressman, 2004; United States, 2000).
Intrinsic dissolution method
Two types of apparatus are described for intrinsic 
dissolution tests: a fixed-disk system and a rotating-disk 
system (Wood’s apparatus) (British Pharmacopoeia, 
2009; European Pharmacopoeia, 2008; United States 
Pharmacopeia, 2010; Viegas et al., 2001). 
Dissolution studies were conducted using the 
Wood’s apparatus, which was originally developed by 
John Wood and enables the calculation of the dissolution 
rate per square centimeter (Wood, Syarto, Letterman, 
1965; Yu et al., 2004; Zakeri-Milani et al., 2009).
During the intrinsic dissolution method development, 
the antiretroviral drugs were subjected to different 
compression force until define the optimal compression 
force. Previous intrinsic dissolution tests indicate that there 
were no changes in the dissolution profiles, indicating 
absence of a polymorphic transition. The compression 
force used was sufficient to form the drug disk, which 
remained stable until its complete dissolution in the media. 
According to Yu and colleagues (2004), the intrinsic 
dissolution method presents robustness and it is not 
influenced by compression force, dissolution volume, 
distance of the drug disk from the bottom of the dissolution 
vessel, and drug disk rotation speed (Yu et al., 2004).
An amount of drug was compressed to make a 
non-disintegrating disk and the exposed surface area was 
0.5 cm². Table I summarizes the conditions used to obtain 
disks for intrinsic dissolution studies for each drug.
For each assay, three vessels were previously 
filled with 900 mL of buffer solution at a temperature 
of 37.0 ± 0.5 ºC with rotation of 50 rpm. Samples were 
withdrawn at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 
40, 45, 50, 55, 60, 70 and 80 min with replacement of 
fresh media. To highly soluble drugs, it was necessary to 
withdraw a known aliquot from the dissolution media and 
make a volumetric dilution before determining absorbance 
values by UV-spectroscopy (United States Pharmacopeia, 
2010; Yu et al., 2004). It is important to consider that 
the solution containing a compound with low solubility 
and high molar absorptivity may be diluted, as solution 
containing a compound with high solubility and low 
molar absorptivity may not be necessarily diluted. Thus, 
the dilution mainly depends on molar absorptivity of the 
drugs (Alves et al., 2010; Filippin, Souza, 2006; Pereira 
et al., 2011; Ruela, Araújo, Pereira, 2009).
TABLE I - Conditions adopted for each antiretroviral drug to obtain disks for intrinsic dissolution study
drug compressed amount (mg) time of compression (min) pressure (psi)
3TC 300 3 3000
d4T 350 2 2000
AZT 200 1 2000
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The cumulative quantity of dissolved drug was 
corrected for each sample interval according to volume 
collected from the each vessel. For IDR values, a graph 
was constructed through accumulated amount of the 
drug dissolved versus time and a linear regression was 
performed. Thus, the dissolution rate was obtained (Issa, 
Ferraz, 2011).
Absorbance values were determined in triplicate 
at the maximum absorbance wavelength. The amount 
dissolved per surface unit of the disk was plotted against 
the time for each dissolution vessel. The slope of the linear 
regression (R2≥0,99, p<0,005) was considered as IDR, 
which can be calculated by equation below:
 
where j is the disk intrinsic dissolution rate, V is the volume 
of the dissolution media, c is the drug concentration, A is 
the disk area, and t is the time (Yu et al., 2004).
RESULTS AND DISCUSSION
Equilibrium solubility method (shake-flask)
In order to set a reliable condition for BCS 
classification of compounds and considering that small 
intestine is the major site for drug absorption, this study 
has considered the pH range of 1.2 to 7.5 for equilibrium 
solubility and intrinsic dissolution studies.
Based on solubility results, it is possible calculate the 
dose:solubility ratio, which represents a volume of media 
necessary to solubilize the highest dose of the administered 
drug. An API (active pharmaceutical ingredient) is 
considered highly soluble when the dose:solubility ratio 
is less than 250 mL (Lindenberg, Kopp, Dressman, 2004; 
United States, 2000) in a pH range of 1.0 to 7.5 (United 
States, 2000) or pH 1.2 to 6.8 (EMA, 2008; WHO, 2005) 
at 37 °C (Strauch et al., 2011).
However, differences may exist in relation to 
the dosages of the drug, depending on the country and 
adopted protocols, which can determine variability in 
the biopharmaceutical classification of a compound. For 
example, due to the higher dose available for a medicinal 
product, the same active substance may be considered as 
high solubility drug in a country and low solubility drug 
in another country (Lindenberg, Kopp, Dressman, 2004; 
United States, 2012; WHO, 2005).
During equilibrium solubility test of d4T, the buffer 
solution pH 1.2 showed, at the end of the test, changes in 
smell and color, suggesting a possible degradation reaction 
due the test conditions (150 rpm 37 °C for 72 hours), thus 
making it impossible to obtain results of solubility in this 
media.
Studies conducted by Silva and colleagues (2008) 
have reported that the main degradation product of d4T is 
thymine. This product is mainly formed after hydrolytic 
and oxidative processes (Silva et al., 2008).
Table II shows solubility results (in mg mL-1) and 
dose:solubility ratio (in mL) for antiretroviral drugs and 
the Figure 1 represents average solubility of 3TC, d4T and 
AZT, respectively.
The recommended dose for 3TC is 300 mg, for 
d4T is 40 mg and for AZT is 300 mg. These substances 
are clearly classified as high solubility drugs at pH 1.2, 
4.5, 6.8, 7.5 and water (except d4T, where solubility in 
pH 1.2 was not possible), since they satisfy the criteria of 
dose:solubility ratio < 250 mL, as demonstrated in Table 
II (United States, 2000; United States, 2012; WHO, 2006).
The results of solubility indicate that 3TC and AZT 
present high solubility characteristics based on FDA 
criteria. By the other hand, d4T presents high solubility 
in water, pH 4.5, pH 6.8, pH 7.5, but the solubility 
determination of d4T was not possible at pH 1.2 due to 
stability problems in this media. Thus, the solubility is 
not a limiting factor for bioavailability of 3TC and AZT 
(United States, 2000).
The stability problems can be identified through 
differences in the smell and color of the solution prepared. 
In the case of d4T, a difference in the smell and color 
of the solution was noticed but for some drugs these 
differences may not be evident. To ensure the integrity of 
the drugs solubilized in the different media studied, the 
antiretroviral drugs were subjected to a stability assay and 
the quantification was performed using a chromatographic 
method (HPLC system Merck-Hitachi LaChrom®, USA).
The stability assay was performed for each drug in 
each media with different pH values. Briefly, the solutions 
were subjected to the conditions of the solubility assay 
considering the time and the temperature. The total time 
of the stability assay was 72 hours at 37 °C. Analyses of 
the solutions were performed at 12, 24, 36, 48, 72 hours 
and the results were compared to standard solutions of the 
drugs freshly prepared. The chromatograms of the drugs 
were equivalent to standard solution of the drugs for 3TC, 
AZT and d4T, except for pH 1.2, where the chromatograms 
indicate significant differences for stavudine.
Solubility data from literature about 3TC, d4T and 
AZT are not easily found. The few existing reports show 
differences that can be justified by: technique or type of 
test used, temperature, composition and pH of the media.
According to Merck Index (2001), the solubility of 
3TC is 70.0 mg mL-1 (at 20 °C) and for AZT is 25.0 mg mL-1 
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TABLE II - Solubility at 37 °C and dose:solubility ratio of 3TC, d4T and AZT for each media used obtained through equilibrium 
method
Drug and dose pH wavelength (nm) solubility (mg mL-1) dose:solubility ratio* (mL)
3TC (300 mg) 1.2 281 212.63 1.41
4.5 275 155.95 1.92
6.8 271 179.03 1.68
7.5 273 190.70 1.57
water 272 177.53 1.69
d4T (40 mg) 1.2 — — —
4.5 266 149.22 0.27
6.8 266 139.43 0.29
7.5 266 130.15 0.31
water 266 146.49 0.27
AZT (300 mg) 1.2 268 18.65 16.08
4.5 269 23.25 12.90
6.8 267 24.43 12.28
7.5 267 20.10 14.93
water 267 25.39 11.82
* Dose:solubility ratio ≤ 250 indicates high solubility related to dose (United States, 2000)
FIGURE 1 - Average solubility of 3TC (A), d4T (B) and AZT 
(C) in water, pH 1.2 (except d4T), pH 4.5, pH 6.8 and pH 7.5.
(at 25 °C). The results presented in this study are different 
from Merck Index, but test conditions such as temperature 
and method can justify theses differences. The temperature 
is a crucial factor, since that this parameter can influence the 
solubility, i.e., if temperature increases, the drug solubility 
is higher (Merck Index, 2001). It is important to note that 
this study followed FDA recommendations.
Singh and colleagues determined the equilibrium 
solubility of AZT in water and in phosphate buffer pH 6.8 
employing the technique of shake-flask under stirring for 
48 hours at temperatures of 37 °C and 25 °C. The results 
indicated that AZT had a solubility of 30.6 mg mL-1 at 
37 °C and 19.5 mg mL-1 at 25 °C in water. In phosphate 
buffer pH 6.8, the solubility was 24.4 mg mL-1 at 37 °C 
and 20.3 mg mL-1 at 25 °C. AZT results of this study are 
in accordance to results presented by Singh and colleagues 
(2010) (Singh et al., 2010).
In another study, Prakash and colleagues (2008) 
examined the solubility of antiretroviral drugs, 3TC, d4T 
and AZT, in different media (purified water, 0.01 M HCl 
solution, acetate buffer pH 4.5 and phosphate buffer pH 
6.8). The results obtained by these authors are presented 
in Table III.
The results described in this work are different than 
those indicated and published by Prakash and colleagues 
(2008). Such differences can be attributed to conditions 
employed for the solubility determination, such as: 
temperature, intensity and kind of stirring, test time, 
composition of the dissolution media.
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As explained above, the solubility determination of 
3TC, d4T and AZT in the present study was performed 
according to FDA guidance (United States, 2000) in an 
incubator with orbital shaking platform. This equipment 
enables the heating of flasks and adequate control of the 
temperature (maintained at 37.0 ± 0.5 °C). Moreover, 
the orbital shaking platform promotes speed control 
(150 rpm). Thus, the conditions adopted in this study 
remained constant and standardized. The stirring time used 
in this work was 72 hours, which is important period to 
reach the saturation of the media.
Furthermore, in studies conducted by Prakash and 
colleagues (2008), the heating of media was located not 
ensuring proper distribution of temperature, and stirring 
was promoted using a magnetic stirrer. It should be noted 
also that the total test time for the cited study was 5 hours. 
Another factor is the dissolution media composition 
(Prakash et al., 2008).
Intrinsic dissolution method
Intrinsic dissolution has been recently studied and 
discussed for solubility determination of a compound as 
an alternative method to equilibrium solubility. Values 
of intrinsic dissolution rate can be used to determine the 
solubility class of a drug (Issa, Ferraz, 2011; Yu et al., 
2004; Zakeri-Milani et al., 2009).
The standardization of intrinsic dissolution test 
should be made carefully because this method is influenced 
by internal and external factors (properties of solid state, 
surface area, hydrodynamic condition, composition of 
dissolution media, vibration, rotation speed, presence of 
dissolved gases in dissolution media, sample sites) (Issa, 
Ferraz, 2011; Souza, Freitas, Storpirtis, 2007). Thus, all 
these conditions were controlled and standardized to 
minimize any interference.
Figure 2 shows a typical plot of amount of drug 
versus time for 3TC, d4T and AZT at different values of 
pH and water. The insignificant discrepancies between 
three runs using three disks in three dissolution vessels 
indicate an excellent reproducibility (RSD less than 10%). 
Linearity was also excellent, which can be demonstrated 
by a correlation coefficient higher than 0.99 for all 
solutions used.
From the dissolution profiles were obtained intrinsic 
dissolution rates (IDR). The IDR speed of the sample 
is determined from the slope of the line (United States 
Pharmacopeia, 2010).
The determined IDR for each drug are shown 
in Table IV. The presence of a sink condition in the 
dissolution media during the experiment is upheld by 
comparison of the final concentration of drugs and their 
solubility in dissolution media.
IDR results showed in Table IV demonstrate a good 
TABLE III - Solubility values obtained from literature (Prakash et al., 2008)
Solubility (mg mL-1)
water HCl 0.01 M pH 4.5 (acetate buffer) pH 6.8 (phosphate buffer)
3TC 140.01 276.08 230.50 92.76
d4T 75.36 78.19 101.23 76.13
AZT 28.90 27.36 21.36 20.10
FIGURE 2 - Amount versus time profile for 3TC (A), d4T (B) 
and AZT (C) at pH values of 1.2, 4.5, 6.8, 7.5 and water.
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TABLE IV - Intrinsic dissolution rate (IDR) of 3TC, d4T and 
AZT.
drug
IDR (mg min-1 cm-2)
pH 1.2 pH 4.5 pH 6.8 pH 7.5 water
3TC 9.83 6.38 5.13 4.86 6.94
d4T 2.74 2.76 2.59 2.43 2.36
AZT 0.74 0.90 0.72 0.66 0.95
qualitative correlation with the equilibrium solubility. 
IDR is a rate phenomenon instead of an equilibrium 
phenomenon. In addition, IDR values correlate more 
closely with in vivo drug dissolution dynamics than 
equilibrium solubility because dose recommended is taken 
into account in this method while the intrinsic dissolution 
does not consider this effect (Issa, Ferraz, 2011).
Thus, when the drug dose is extremely high or 
extremely low (for exemple 1.0 mg mL-1 and recommended 
dose of 0.25 mg or 4.0 mg mL-1 and recommended dose of 
1000 mg) a discrepancy between the equilibrium solubility 
and the IDR may occur. Further, when the drug dose is 
extremely high, the in vivo absorption may be limited by 
solubility (Singh et al., 2010).
At least 10 points were used for the construction 
of intrinsic dissolution profiles of drugs. Due to the high 
rate of dissolution, short intervals were imposed to reach 
sampling points and obtain meaningful results. 3TC and 
d4T presented higher dissolution speed compared to AZT, 
which takes a longer time to reach 10% of dissolution 
(United States Pharmacopeia, 2010).
As regard to IDR, it is noteworthy that there are no 
reports in the literature about the intrinsic characteristics 
of antiretroviral drugs dissolution but it possible to find 
limits to characterize high soluble drugs.
According to Yu and colleagues (2004), compounds 
which have IDR greater than 0.1 mg min-1 cm-2 can be 
classified as highly soluble substances. Based on this 
information, all antiretroviral drugs studied can be classified 
as highly soluble compounds in all dissolution media due to 
IDR values higher than 0.1 mg min-1 cm-2 (Yu et al., 2004).
Another study developed by Zakeri-Milani and 
colleagues (2009) suggests that drugs with IDR value 
higher than 1 mg min-1 cm-2 can be considered as highly 
soluble substances, while compounds with low solubility 
show an IDR value lower than 1 mg min-1 cm-2 (Zakeri-
Milani et al., 2009).
Equilibrium solubility versus intrinsic dissolution
In recent years, solubility and permeability studies 
have received focus from scientific community due to BCS 
and, consequently FDA guidance for biowaiver purposes. 
Thereby, comparison between equilibrium solubility 
and intrinsic dissolution methods has been grown, since 
that solubility is a crucial factor for the absorption (and 
bioavailability) of drugs.
Equilibrium solubility presents some factors 
that can difficult the achievement of results, such as: 
temperature, filtration processes, substance characteristics 
(as crystalline structure or salts formation) (Baka, Comer, 
Takács-Novak, 2008; Issa, Ferraz, 2011; Yu et al., 2004). 
However, this does not allow obtain a solubility profile 
of drugs or identify their amorphous because it is an 
equilibrium condition that must not be interfered during 
the test (sampling is not possible), otherwise result in the 
impairment of reliable data (Issa, Ferraz, 2011).
Although equilibrium solubility method adopts 
physiological conditions as temperature and solution pH, 
other aspects must be observed. The temperature is a factor 
that interferes a lot in this test and the loss of temperature 
can cause the appearance of crystals and loss of equilibrium 
condition, compromising results. The intrinsic dissolution 
test, the same temperature and solutions are used but it is 
a safer method because the loss of temperature causes no 
major influences compared to equilibrium test because the 
dissolution media is not saturated.
In addition, the test time is too long (until 72 hours) 
in equilibrium method and the amount of drug used for 
this study is very high compared to intrinsic dissolution, 
which requires a less amount of drug (which is suitable 
for the early stages of development of new compounds). A 
less amount of drug in intrinsic solution allows realize any 
interference in the results due to factors such as any change 
in crystalline structure or salts formation characterized by 
deviation from linearity (Issa, Ferraz, 2011; Yu et al., 2002; 
Yu et al., 2004; Zakeri-Milani et al., 2009).
The conditions of amount of drug and dissolution 
media volume deviate from the in vivo condition because the 
administered drug does not remain so long in the dissolution 
step in the stomach and the substance does not saturate 
the dissolution media in vivo. In intrinsic dissolution, the 
volume of dissolution media is major than equilibrium 
method and the dissolution of drug is constant and linear.
This is an important point to be discussed and more 
deeply studied. Based on d4T results obtained in this study, 
intrinsic dissolution allowed the solubility study, whereas 
in equilibrium study the determination of solubility was 
not possible due to degradation suffered by this drug. The 
media volume of buffer and no saturation of dissolution 
media indicate that intrinsic dissolution can be used to 
study the behavior of sensitive drugs.
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CONCLUSION
The BCS was developed based on two properties: 
solubility/dissolution rate and intestinal permeability of 
drugs. In this study, 3TC, d4T and AZT were assessed by 
two methods for solubility study: equilibrium solubility 
and intrinsic dissolution. Based on results, 3TC and AZT 
present high solubility characteristics in equilibrium 
solubility, which was confirmed by intrinsic dissolution 
(high speed of dissolution). The solubility determination 
of d4T in pH 1.2 was not possible due to stability problems 
in equilibrium solubility method. Based on FDA criteria, a 
drug must be soluble in a pH range of 1.0 – 7.5 at 37 °C and 
the d4T does not match this criteria. By the other hand, d4T 
did not present any inconvenience in intrinsic dissolution 
method and d4T presents high speed of dissolution as 
3TC and AZT.
According to discussed in this study, IDR has 
demonstrate adequate method for solubility studies instead 
equilibrium solubility method, since these method does 
not consider dose effect of drug. Thus, the behavior of 
drugs can be predicted through IDR because this method 
is closest to in vivo conditions.
Yu and colleagues (2004) consider 0.1 mg min-1 cm-2 
as a boundary value, while Zakeri-Milani and colleagues 
(2009) consider 1.0 mg min-1 cm-2 for classification of a 
drug according to their intrinsic solubility. Then, based on 
Yu and colleagues, 3TC, d4T and AZT may be considered 
as highly soluble drugs. On the other hand, when the 
boundary value proposed by Zakeri-Milani and colleagues 
is considered, 3TC and d4T may be considered as highly 
soluble drugs, while AZT may be considered a compound 
of low solubility.
According to FDA, a criterion which is based 
on Biopharmaceutical Classification System, AZT is 
classified as highly soluble drug (Soares et al., 2013), 
since the equilibrium method is employed for solubility 
studies. As intrinsic dissolution is not yet used for 
regulatory purposes, this study aimed to discuss the 
feasibility of this technique and once appropriately 
standardized, may be accept as an alternative methodology 
for equilibrium solubility assay of drugs. Moreover, the 
intrinsic dissolution is a rate phenomenon, different from 
the equilibrium solubility (Yu et al., 2004; Zakeri-Milani 
et al., 2009).
Due to great diversity of drugs with different 
physicochemical characteristics, a limit value is difficult 
to be purpose and it depends on data and more consistent 
studies, as discussed by Yu and colleagues (2004). The 
establishment of a boundary value for intrinsic dissolution 
is still considered a challenge, which is being explored 
by researchers and the results of these studies are being 
published in the literature.
In this study, we emphasize that conditions adopted 
to obtain intrinsic dissolution results is in according to 
conditions described in the study published by Yu and 
colleagues (2004), where variables were evaluated, 
determining the robustness of the method.
In summary, the data obtained from the intrinsic 
dissolution test confirm the results obtained in equilibrium 
solubility when a boundary value of 0.1 mg min-1 cm-2 is 
considered and the drugs can be classified as highly soluble 
substances, as proposed by Yu and colleagues (2004) (Yu et 
al., 2004). Based on the boundary value (1 mg min-1 cm-2) 
proposed by Zakeri-Milani and colleagues (2009), 3TC 
and d4T can be classified as highly soluble drugs, while 
AZT would be considered as low solubility drug (Zakeri-
Milani et al., 2009).
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